Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 10—October 2018
Research

Candida auris in Healthcare Facilities, New York, USA, 2013–2017

Eleanor Adams, Monica Quinn, Sharon Tsay, Eugenie Poirot, Sudha Chaturvedi, Karen Southwick, Jane Greenko, Rafael Fernandez, Alex Kallen, Snigdha Vallabhaneni, Valerie Haley, Brad Hutton, Debra Blog, Emily LutterlohComments to Author , Howard Zucker, and Candida auris Investigation Workgroup1
Author affiliations: New York State Department of Health, New Rochelle, New York, USA (E. Adams, K. Southwick); New York State Department of Health, Albany, New York, USA (M. Quinn, S. Chaturvedi, V. Haley, B. Hutton, D. Blog, E. Lutterloh, H. Zucker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Tsay, E. Poirot, A. Kallen, S. Vallabhaneni); New York City Department of Health and Mental Hygiene, New York, New York, USA (E. Poirot); New York State Department of Health, Central Islip, New York, USA (J. Greenko); New York State Department of Health, New York (R. Fernandez); State University at Albany School of Public Health, Albany, New York, USA (V. Haley, D. Blog, E. Lutterloh)

Main Article

Table 1

Selected concurrent medical conditions and medical interventions for 51 persons with Candida auris infection, New York, USA, 2013–2017

Characteristic No. (%) persons
Concurrent condition
Respiratory insufficiency requiring support 33 (65)
Mechanical ventilation at time of diagnosis 17 (33)
Neurologic disease* 24 (47)
Diabetes 18 (35)
Malignancies 11 (22)
Colon cancer 5 (10)
End-stage renal disease 8 (16)
Hemodialysis 7 (14)
Kidney transplant 1 (2)
Decubitus ulcers 10 (20)
Otitis with complications
 2 (4)
Medical interventions
Hemodialysis 7 (14)
Central venous catheter within 7 d before first positive culture for C. auris 31 (61)
Gastrostomy tube at time of diagnosis 27 (53)
Receipt of systemic antifungal medication within 90 d before first culture positive for C. auris 25 (49)
Receipt of systemic antibiotics within 14 d before first culture positive for C. auris 42 (82)

*Includes seizure disorder (n = 8), cerebrovascular accident (n = 7), dementia (n = 4), anoxic brain injury (n = 3), spinal cord injury (n = 2), and 1 case each of Parkinson’s disease, multiple sclerosis, Huntington’s disease, Guillain-Barré syndrome, traumatic brain injury, pituitary tumor, and neuropathy.

Main Article

1Additional members of the workgroup are listed at the end of this article.

Page created: September 12, 2018
Page updated: September 12, 2018
Page reviewed: September 12, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external